1 / 53

Hyperbaric Oxygen in ORL-HNS: Facts, Fictions, and Evidence

Hyperbaric Oxygen in ORL-HNS: Facts, Fictions, and Evidence. Evan R. Ransom, MD University of Pennsylvania Otorhinolaryngology, Head & Neck Surgery Faculty Discussant: Kevin Hardy, MD Emergency Medicine, Hyperbaric Medicine. Overview. Why HBO2? History Basics Details

abney
Download Presentation

Hyperbaric Oxygen in ORL-HNS: Facts, Fictions, and Evidence

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Hyperbaric Oxygen in ORL-HNS:Facts, Fictions, and Evidence Evan R. Ransom, MD University of Pennsylvania Otorhinolaryngology, Head & Neck Surgery Faculty Discussant: Kevin Hardy, MD Emergency Medicine, Hyperbaric Medicine

  2. Overview • Why HBO2? • History • Basics • Details • ORL-HNS Applications • Data • Discussion

  3. History • Initial discovery • 1662  Henshaw built first hyperbaric chamber • English physician and clergyman • Called the chamber the “Domicilum” • Hermetically sealed box with organ bellows & valves • "In times of good health this domicilium is proposed … to promote insensible respiration, to facilitate breathing and expectoration … of excellent use for prevention of most affections of the lungs."

  4. Background • Elemental Oxygen • 1775  Discovered by Priestly (English) • Surgical use • 1870’s  Fontaine & Bert (France) • Prolong anesthesia • Improved surgical outcomes • Wound healing • Infection rates • Decompression sickness • 1910-30’s Drager, then Behnke & Shaw • Reduced morbidity of decompression • Studies of cardiopulmonary effects initiated

  5. Background • Cardiothoracic Surgery • 1950’s  Boerema (Dutch) • Increase tissue oxygen stores prior to cross-clamping • Repair of congenital heart defects • With Brummelkamp, discovered effects on anaerobes • Bacteriostatic • Treat gas gangrene (Clostridium perfringens) • Carbon monoxide poisoning • 1962  Smith & Sharp (English) treated coal minors exposed to carbon monoxide • US Military Research • 1930’s  determine maximal pressure tolerated • 1960’s  potentiation of radiation doses

  6. Common Current Uses • Decompression Sickness • Gas Embolism • Crush Injuries • Anaerobic Infections • Osteomyelitis • Chronic Wounds • Necrotizing Infections • Osteoradionecrosis

  7. Theory • Why did we think HBO2 would work? • Respiration is good… so why not more of it? • What if we increase tissue oxygen delivery to supraphysiologic levels? • How about generating more reactive oxygen to kill pathogens and tumors!?

  8. Theory • Some physics we’ve all forgotten… • Boyle’s Law • Dalton’s Law • Henry’s Law

  9. Physics • Boyle’s Law at a constant temperature, the pressure and volume of a gas are inversely proportional. • Hyperbaric chamber • Compression of a given volume of gas therefore elevates its pressure • One-way valve to add gas volume to chamber

  10. Physics • Dalton’s Law in a gas admixture, each component gas exerts a pressure proportional to its fraction of the total volume (i.e., partial pressure). • Increasing the proportion of oxygen in the inhaled gas mixture increases its partial pressure • Air at sea level is 21% O2 • HBO2 treatments use FiO2 100%

  11. Physics • Henry’s Law the amount of gas dissolved in a liquid is directly proportional to its partial pressure at the liquid/gas interface. • Increasing the partial pressure of oxygen results in more oxygen dissolved in the blood • Blood oxygen carriage therefore increases • In addition to saturation of available hemoglobin

  12. Physiology • Cardiopulmonary • Increase in PaO2 • Saturation of available hemoglobin molecules • Hgb 97% saturated at atmospheric pressure • Maximization does NOT significantly increase O2 delivery • Increase in dissolved O2 • PAO2 is 100mm Hg at atmospheric pressure • Using 100% FiO2 at 3 atm  up to 2000mm Hg • Increase O2 from 3ml/L blood to to 60ml/L • 20 times more O2 circulating in plasma

  13. Physiology Cardiopulmonary Dissolved O2 diffuses into RBC-impassible areas May also deliver O2 in absence of functional Hgb 100% O2 at 3.0atm  effects at capillary beds Doubles distance of venous diffusion Quadruples distance of arteriolar diffusion

  14. Physiology • Tissue & Cellular level • Tissue PO2 is 55mm Hg at atmospheric pressure • Using FiO2 100% at 3atm, increase to 500mm Hg • Almost 10 fold increase in tissue oxygen tension • Tissue PO2 > 40mm Hg needed to initiate any healing • Tissue response proportional to O2 delivery • O2 diffuses down the partial pressure gradient • Gradient from arterioles  capillary bed  venous return is increased 37 fold • Increase activation of fibroblasts & osteoblasts • Promotes angiogenesis & neovascularization

  15. Mechanism • Three main effects of HBO2: 1) Delivery of O2 to hypoperfused tissues • Limit ischemic damage, cell death, and inflammation • Promotes collagen synthesis and angiogenesis • Decreases lactate production and tissue acidosis 2) Generation of oxygen free radicals • Aids in oxygen-dependent killing of bacteria • Facilitates oxygen dependent transport of antibiotics 3) Vasoconstriction • Limits leukocyte adhesion and degrannulation • Decreases tissue edema

  16. Dosing and Delivery • Parameters • All regimens use 100% O2 • Pressure more variable • Most use 2.4 atm • Maximum tolerated is 3 atm • 4 atm induces seizures Monoplace Hyperbaric Chamber.

  17. Dosing and Delivery • Common regimens • Dives between 30 and 120 minutes • May be daily or BID • Total number varies by indication • Most treatments around 30 dives • Optional addition of 10 or more dives • Monoplace vs. multiplace chambers Multiplace Hyperbaric Chamber.

  18. Contraindications • One absolute contraindication • Pneumothorax • Pressure converts to tension pneumothorax • Circulatory disruption and collapse • All patients get screening CXR • Relative contraindications • History of spontaneous pneumothorax • History of throacic surgery • Concurrent URI • Emphysema and COPD • Seizure disorders

  19. Complications • Barotrauma • Middle ear • Eustachian tube dysfunction or obstruction • Poor pressure equalization • May cause • Significant pain • Hemotympanum • TM rupture

  20. Complications • Barotrauma • Lung parenchyma • Elevated pressures may damage alveoli • Alveolar hemorrhage • Hemoptysis • Pneumonitis • Alveolar rupture • Pneumothorax • Pulmonary interstitial emphysema Tension Pneumothorax

  21. Complications • Lens deformation causes temporary myopia • Exacerbation of other processes • Dental abscess, sinusitis, laryngocele, etc. • Claustrophobia, anxiety, etc. • Oxygen toxicity • Very rare, but may cause seizures • Potential effects on tumor growth • Controversial – more on this later…

  22. Fire Risk • Perfect set up for fire (especially monoplace) • 100% oxygen • Highly pressurized • Enclosed space • Rare… but not rare enough • 50 deaths due to HBO2-related fires since 1980 • Must remove all flammable materials • Fire safety protocol is essential • Risk reduced in multiplace chambers • Chamber pressurized • O2 delivered individually via tight-fitting masks • Attendants may enter in an emergency

  23. Costs • HBO2 is relatively expensive… • Monoplace chamber > $150,000 • Most facilities have multiplace chambers, which can cost millions • Each 30 min costs ~ $170 • Average full course is 30 dives of 90 min • Billed for ~$15,300 • Plus physician fees, hospital stay, meds, etc. • But… • Medicare reimburses for most accepted indications

  24. Costs • Cost efficacy analyses • Studies from Europe, Canada, & Japan • Significant cost savings for multiple indications • E.g., osteoradionecrosis of the mandible • Reduced surgical costs in ORN patients • Reduced length of stay • Overall 17% cost reduction in Europe • U.S. studies focus on diabetic foot ulcers • HBO2 cost effective for this indication • Very limited U.S. data for ORL-HNS indications

  25. Applications • Proposed or Studied for ORL-HNS • Osteoradionecrosis • Chondroradionecrosis • Enhancement of graft & flap viability • Necrotizing infections • Chronic wounds • Fistulas • Malignant otitis externa • Skull base osteomyelitis • Sudden SNHL • Tinnitus • Idiopathic facial paralysis (Bell’s palsy) • Radiation sensitization

  26. Applications Today’s review • Osteoradionecrosis • Pharyngocutaneous fistulas • Enhancement of graft & flap viability • Malignant otitis externa • Sudden SNHL • Radiation sensitization

  27. Osteoradionecrosis • Damage to osteocytes from XRT • Weakens bone, predisposing to fracture • Often painful, broken down mucosal coverage • Decreases blood flow, difficult to fight infection • Body of the mandible most affected • Least redundant blood supply & muscle coverage • Incidence decreased significantly in last 30 years • Lower radiation doses, more targeted fields • Currently less than 5% of patients receiving H&N XRT

  28. Osteoradionecrosis • Pathophysiology • Significant fibrotic changes in bone and marrow • Reduction in caliber & number of feeding vessels • Periosteal & mucosal damage  bone necrosis ORN X-ray – Mandible ORN Histology – Mandible

  29. Osteoradionecrosis • HBO2 used for ORN since 1960’s • Multiple staging systems & treatment regimens • Marx, et al. 1982, 1983, 1990 (retrospective) • Sequential treatment combining HBO2, debridement, surgical resection & reconstruction • Over 90% success rate • Neovius, et al. 1997 • Cured 12/15 patients with ORN, CRN, or tissue necrosis • Combination HBO2, wound care, debridement, antibiotics • Significant improvement over historical controls (7/15) • Conservative measures alone

  30. Osteoradionecrosis Not all data agree (Annane, et al. 2004) Prospective, randomized, controlled trial enrollment after 2 months conservative Tx 30 dives for 90 min at 2.4 atm vs. placebo Placebo = Pressurized 90% Nitrogen No significant difference between groups!? Was there a biologic effect of the placebo? Not enough dives?

  31. Osteoradionecrosis • Cochrane review 2005 • Outcome measures Primary: Survival, resolution of disease Secondary: Mucosal coverage, bony continuity, pain (poor data) • Identified 6 trials that met evidence standards • Treatment algorithms differed slightly • Pooled data for mandible • 92% resolution with HBO2, 65% in control group • Improved mucosal coverage (93% v. 67%) • RR 1.4 (95%CI 1.2-1.6, p< 0.001); NNT = 4 • Improved bony continuity (92% v. 65%) • RR 1.4 (95%CI 1.1-1.7; p=0.009); NNT = 4 • Conclusion: HBO2 is safe and likely effective for ORN

  32. Chronic Wound Data • Relatively little data from H&N • Cochrane review 2005 • Lower incidence of wound dehiscence with HBO2 • 6% v. 37% post-XRT for H&N SCCA • Significant result only in subset with flaps or grafts • Limited data on speed of healing, major vessel bleeding, decannulation, or need for laryngectomy • Implies that HBO2 would be useful in H&N reconstruction specifically

  33. Chronic Wound Data • Generalizing from other fields • Diabetic foot ulcers • Significant reduction in morbidity • Significant improvement in functional outcomes • Significant cost savings • Mechanism shown in laboratory analyses • Enhances fibroblast activity • Collagen synthesis • Neovascularization • Improves infection control (especially anaerobes] • Treatment response can be predicted • Based on measurement of tissue PO2 (TcPO2) • >40mm Hg predicts at least some response

  34. Pharyngocutaneous Fistula • Post-laryngectomy • Significant increases • Morbidity • Cost • Incidence • Varies widely (3% to >50%) • Consensus 10-15% • Pathophysiology • Incomplete healing or breakdown of pharyngeal suture line • Connection develops between mucosa and skin • First sign is generally post-op fever Post-laryngectomy Fistula

  35. Pharyngocutaneous Fistula Complications Major vessel bleed Aspiration pneumonia, infection, sepsis NPO status associated with poor patient QOL Treatment Most fistulas respond to conservative measures NPO & enteral nutrition Local wound care & antibiotics Delayed surgical closure Non-healing fistulas Large fistulas Local rotational flaps Pectoralis major flap Hyperbaric oxygen? Prophylactic? Adjuvant?

  36. Pharyngocutaneous Fistula • Davis, et al. 1979 • 15/16 patients with soft tissue necrosis neck post-XRT • Poor patient descriptions, scant wound documentation • Marx, et al. 1993 • Tested prophylactic HBO2 in post-XRT resections • Prospective with80 patients, 80 controls • Decreased rate and severity of wound complications • 11% dehiscence in HBO2 vs. 48% without • 6% infections in HBO2 vs. 24% without • 11% prolonged hospital stay in HBO2 vs. 55% without • Neovius, et al. 1997 • 15 patients with post-XRT wounds • 4/5 patients with fistulas healed (3/4 with pharyngocutaneous) • Narzony, et al. 2005 • 8 post-XRT patients successfully treated with HBO2 • 1 pt had a post-laryngectomy fistula & polymicrobial infection • Partially closed with HBO2, infection fully treated • Definitive closure with local muscle flap post-HBO2

  37. Pharyngocutaneous Fistula Limitations Small {N}, patients grouped (i.e., not all fistulas) Timing and dosing of therapies differ Mostly retrospective data Penn Study (ORL-HNS, Hyperbaric Medicine) Post-radiation laryngectomy Effects of HBO2 on wound status & outcome Prospective data Predictive model for wound healing Tissue hypoxia Angiogenesis

  38. Skin Grafts & Free Flaps • Pathophysiology • Grafted or transplanted tissue may be healthy • But… implantation site may be hypoxic • Due to tissue bed disease, vasospasm, edema, infection • Oxygen & nutrient supply compromised • Must establish vascular connection for survival • HBO2 Mechanism • Improves tissue PO2 • Promotes angiogenesis • Augments immune response & limits inflammation

  39. Skin Grafts & Free Flaps Compromised skin grafts & flaps Ueda, et al. 1987 Retrospective: HBO2 post-OC composite resection 95-100% recovery of compromised flaps & grafts Waterhouse, et al. 1993 Retrospective: HBO2 for salvage of ischemic free flaps HBO2: 75% salvage vs. 46% without Tx within 24hrs  100% survival rate Tx > 72hrs  0% survival Marx, et al. 2002 Prospective, randomized post-XRT resection 11% wound healing delay HBO2 vs. 55% without 3.5% major wound dehiscence HBO2 vs. 33% without 2.5% major wound infection HBO2 vs. 16% without

  40. Malignant Otitis Externa • Data is of poor quality • Mostly case reports • No prospective data • But… • Supports use • Need prospective data • Need standardization

  41. Malignant Otitis Externa • Cochrane Review 2005 • Data poor quality • No control groups • No randomization • All retrospective • Suggestion of effect • Well-characterized and plausible mechanism • Improved efficacy of immune response • Enhancement of bacteriacidal antibiotic effects • Conclusion: Need RCTs to truly evaluate this indication

  42. Sudden SNHL • Cochrane review 2007 • Data is of poor quality • Found 6 trials meeting minimum standards • Conflicting data in hearing recovery • No difference in improvement of 50% on PTA • Significant difference of 25% on PTA • 22% greater chance of this amount of hearing improvement • Clinical significance? (NNT =5) • Data do not support use in chronic idiopathic SNHL • Summary • Routine use not recommended due to effect size relative to costs • Need larger trials with randomization to determine efficacy

  43. Radiation Sensitization • Among first studied uses of HBO2 (1960’s) • Areas of hypoxia in tumors are resistant to therapy • Increasing oxygen pressure in the tumor can aid tumoricidal therapies • Increase FiO2, increase ambient pressure (i.e., HBO2) • Administration of radiation sensitizing agents (oxygen donors) • Radiation concurrently (i.e., in HBO2 chamber) • Technical difficulties (equipment) • Multiple XRT regimen & HBO2 parameters • Overall suggestion of survival benefit in the literature

  44. Radiation Sensitization • Systematic review (Bennett, et al. 2008) • Found 19 randomized trials of HBO2 with XRT • H&N, cervix, bladder, rectum, esophagus, brain • H&N • Significant mortality reduction (1 & 5 yrs) • Difference seen between fractionization protocols • >12 : trend to significance • <12 : RR 0.69 (95%CI 0.53-0.89, p=0.004), ARR 20.9% • Significant decrease in recurrence (1 & 5 yrs) • Side effects are amplified, too… • Significant increase in radiation morbidity • ORN, tissue necrosis, xerostomia, etc.

  45. Radiation Sensitization • Data support survival effect • Need more RCTs to determine • Timing of XRT (Concurrent? Sequential?) • Fractionization & dosing • Is it worth the costs? • XRT side effects are already difficult… • Saving more lives with lower QOL??? • More complications = higher treatment costs

  46. Tumor Growth!? • Theoretical & historical concern • HBO2 in malignancy • Microscopic disease, positive margins, metastasis • Does HBO2 improve tumor survival? Enhance growth? • Data are conflicting • Handful of case reports suggest growth • GYN malignancies mostly, a couple in H&N CA • Other reports suggest tumor suppression • Currently, experiments do not show tumor progression • Animal models • Human SCCA cell cultures • Systematic reviews have failed to support this concern

  47. Tumor Growth!? • Schonmeyr, et al. 2008 • H&N SCCA cell culture & xenotransplantation • Measured growth • In culture & in mice (tumor implanted on flank) • HBO2 90 min/day for 8 days at 2.1 atm, 100% FiO2 • No significant difference in culture or mouse • No significant difference in • DNA synthesis • Angiogenesis • Trend toward less tumor hypoxia in treatment group • This did not translate to tumor growth • May actually be helpful for XRT or certain chemotherapeutics

  48. Summary • HBO2 derives its clinical benefit via • Increase in the oxygen delivery to hypoxic tissue • Promoting native mechanisms of healing • Decreasing tissue edema & reperfusion injury • Dosing • Most commonly 30-40 dives of 90 min at 2.4atm • Costs • Significant, yet analyses support cost savings in proven indications

  49. Summary • Supported ORL-HNS indications • ORN & CRN, radiation soft tissue injury • Flap & graft survival • Unsupported ORL-HNS indications • Sudden SNHL, tinnitus, Bell’s palsy • Areas of uncertainty • Likely effect: MOE & skull base osteo, fistulas • Poor side effect profile: radiation sensitization

  50. Summary • Further research • Molecular mechanism incompletely understood • Animal studies • Human tissue bank studies • Need ethical randomized control trials • Variety of indications • More combination regimens for cancer treatment & post-XRT reconstruction salvage • What are the optimal dose & delivery shemes? • Maximize oncologic control & quality of life

More Related